-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
On September 17, the official website of CDE showed that the clinical trial application for new indications of Hengrui SHR-1701 injection was approved by the Food and Drug Administration, combined with irinotecan liposomes for PD-1/PD-L1 monoclonal antibody combined with platinum Patients with locally advanced or metastatic esophageal squamous cell carcinoma who have failed first-line chemotherapy
.
SHR-1701 is an anti-PD-L1/TGF-βRII bifunctional fusion protein that blocks the PD-1/PD-L1 pathway and neutralizes the negative effects of TGF-β, PD-1 and TGF-β in the tumor microenvironment The co-inhibition of signals brings about a more effective anti-tumor immune response than any single pathway inhibition
.
At the same time, it can promote the activation of effector T cells, improve the immune regulation in the tumor microenvironment, and ultimately effectively promote the immune system to kill tumor cells
Previously, in the 2021 semi-annual report of Hengrui De, the main clinical research and development pipeline of SHR-1701 injection was announced in detail
.
At present, the clinical progress for two indications of advanced colorectal cancer, advanced or metastatic gastric cancer or gastroesophageal junction cancer is the fastest, and it is in the phase III clinical stage
Irinotecan liposome is an improved innovative drug developed by Hengrui.
The inhibitor of topoisomerase 1 is encapsulated in a phospholipid bilayer vesicle or liposome
.
As a new type of drug carrier for preparations, liposomes have the function of protecting the active structure of the lactone ring, passive targeting and slow drug release characteristics
